Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
US11492384B2 · kind B2 · utility
1Cited by
1References
21Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Sep 16, 2019 |
| Grant date | Nov 8, 2022 |
| Priority date | — |
| Expiry date | Feb 24, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/31
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is a fusion protein comprising IL-2 protein and CD80 protein. A fusion protein comprising CD80 fragment, immunoglobulin Fe, and an IL-2 variant can activate immune cells, such as natural killer cells, and at the same time, can control immune cell regulatory activity of regulatory T cells. Therefore, a pharmaceutical composition comprising the fusion protein as an active ingredient is very industrially useful in that such pharmaceutical composition can increase immune activity in the body, and thus can be effectively used against infectious diseases as well as cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.